Winner
LiBRA 2019: Looking Beyond the Joint in Rheumatoid Arthritis (RA): Is There a Missing Link in RA Management?
Summary of work
RA is a chronic disease affecting up to 1% of the worldwide population. Along with swollen, painful joints, most patients suffer other medical complications including cardiovascular disease, depression and diabetes, that considerably impact their quality of life. Even with therapeutic advances, up to 40% of patients experience suboptimally controlled disease.
Sanofi Genzyme Regeneron, assisted by Team Unity – a Lucid Group Company, launched LiBRA, an international education programme that aims to drive clinical practice change to achieve better RA disease control. Insights highlighted that (i) rheumatologists face barriers that prevent them from helping patients to achieve optimal disease control; (ii) a tailored, personalised approach is needed to support delegate clinical practice change.
LiBRA 2019 employed tactics known to be engaging and memorable and to reinforce behaviour change – we took rheumatologists on a comprehensive, innovative journey that would ultimately inspire them to address the missing links in their clinical practice. 80% of delegates committed to implement clinical practice change and were fully supported by their MSLs through personalised follow-up. Delegate and MSL feedback demonstrated LiBRA is succeeding in its aim to provide a programme that adds real value to the rheumatology clinical community, and ultimately improve outcomes for people with RA.
Judges’ comments
LiBRA 2019 is an outstanding entry, founded on robust insights and really focused on clinical practice improvements. The judges felt that the active MSL follow-up and the accompanying publication really enhanced and extended the learning journey for delegates. This was all underpinned by a great creative strategy, focusing on the concept of nature vs. nurture. An exceptional programme, designed to meet unmet needs in patient management!
